Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston from March 6 – 8, 2023. The chat is scheduled for March 6 at 2:10 PM ET and will be available via webcast. Additionally, the management team will hold one-on-one investor meetings at the event. Vera focuses on developing transformative treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting conditions like IgA nephropathy and lupus nephritis. A replay of the event will be accessible for 90 days on their website.

BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, which is taking place in Boston, MA from March 6 – 8, 2023. The management team will also participate in one-on-one investor meetings.

Fireside Chat Details:

Date:	Monday, March 6, 2023
Time:	2:10 PM ET
Webcast:	https://wsw.com/webcast/cowen132/vera/2010876

A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Uncapped Communications
uncappedverateam@uncappedcommunications.com

FAQ

When is Vera Therapeutics participating in the Cowen 43rd Annual Health Care Conference?

Vera Therapeutics will participate in the conference from March 6 – 8, 2023, with a fireside chat on March 6 at 2:10 PM ET.

How can I watch the Vera Therapeutics fireside chat?

You can watch the Vera Therapeutics fireside chat via webcast at https://wsw.com/webcast/cowen132/vera/2010876.

What is Vera Therapeutics focused on?

Vera Therapeutics is focused on developing treatments for serious immunological diseases, including IgA nephropathy and lupus nephritis.

What is the lead product candidate of Vera Therapeutics?

Vera's lead product candidate is atacicept, which is aimed at treating autoimmune diseases.

Where can I find more information about Vera Therapeutics?

More information about Vera Therapeutics can be found on their website at www.veratx.com.